Q3 FY26 Results · Financial Year Apr 2025–Mar 2026
RPG Life Sciences:
₹180 Cr Revenue. But That Fire Incident.
When Your Manufacturing Gets Too Hot (Literally)
Mid-sized pharma company with decent brands, 32.8% ROCE, and zero debt. But when you own a manufacturing plant, sometimes the universe sends a literal reality check. Fire, resignations, and now a whole API business spun out. Very normal Tuesday.
Market Cap₹3,133 Cr
CMP₹1,892
P/E Ratio29.8x
Div Yield1.05%
ROCE32.8%
01 — At a Glance
The Pharma Company That Got Burned (& Not in the Good Way)
- 52-Week High / Low₹2,725 / ₹1,764
- Q3 FY26 Revenue₹180 Cr
- Q3 FY26 PAT₹22.5 Cr
- Q3 EPS₹13.38
- Annualised EPS (Q3×4)₹53.5
- Book Value₹335
- Price to Book5.65x
- Dividend Yield1.05%
- Debt / Equity0.00x
- 3yr Profit CAGR31.5%
Auditor’s Opening Note: RPG Life Sciences closed Q3 FY26 with ₹180 crore revenue (+4.2% QoQ) and ₹22.5 crore PAT—a -18.3% YoY decline thanks to a manufacturing fire incident at the API facility in Navi Mumbai back in January 2025. But here’s the thing: the company is debt-free, boasts 32.8% ROCE, generates consistent profits, and recently created a ₹105 crore WhatsApp— wait, Wholly Owned Subsidiary (WOS) to spin out the API business by March 2026. This is either genius restructuring or corporate chaos. Your money, your call.
02 — Introduction
The Mid-Sized Pharma Darling That Keeps Surprising You
RPG Life Sciences is what happens when a 45-year-old successful industrialist (Harsh Vardhan Goenka) decides: “You know what? Pharma is cool. Let me build this.” The result? A modestly scaled, debt-free pharmaceutical company with leadership positions in niche therapies—immunosuppressants, gastroenterology, nephrology, rheumatology, oncology, pain management—the whole shebang.
Three manufacturing facilities. Approvals from WHO, EU GMP, TGA Australia, PMDA Japan. 100,000+ doctors on their digital platform (RPG Serv). Strong brands like Azoran, Naprosyn, Lomotil, Aldactone. And revenues that have grown at 12% CAGR over the past 5 years while maintaining 20-25% operating margins like clockwork. Boring? Yes. Profitable? Absolutely.
Then came January 2025, when a fire incident at their Navi Mumbai API facility decided to crash the Q4 FY25 party. Loss insured at ₹16.33 crore. A new CEO appointment in November 2024 (Ashok Nair replaces Yugal Sikri, who retired after 7 years). CFO Vishal Shah resigned in October 2025, only to be replaced immediately. And now—December 2025—they’re spinning out the entire API business into a separate WOS with ₹105 crore capex and a handoff by March 31, 2026. This is not your grandmother’s pharmaceutical company; this is your grandmother’s pharmaceutical company after three espressos and a life coach consultation.
Concall Reality Check (Jan 2026): Management explicitly stated they are “focused on execution” across 10 parallel transformation projects. Nobody sounded panicked. Everyone sounded tired. This is peak corporate India—multiple fires burning, literally and figuratively, handled with the calm of a Delhi auto-driver during monsoon traffic.
03 — Business Model: Boring by Design
Three Simple Bets: India, Emerging Markets, and Specialty Molecules
Members get full access to every article.
